Los Angeles Capital Management
IGMS

Los Angeles Capital Management’s IGM Biosciences IGMS Stock Holding History

Los Angeles Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,400
Closed -$421K – 1432
2021
Q3 		$421K Hold
6,400
– – ﹤0.01% 1136
2021
Q2 		$532K Buy
+6,400
New +$474K ﹤0.01% 1140

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Los Angeles Capital Management's IGMS Position: Q4 2021 in Review

Los Angeles Capital Management sold out of IGM Biosciences (IGMS) in Q4 2021, closing a stake of 6,400 shares — an estimated $421K sold.

Los Angeles Capital Management first reported a position in IGMS in Q2 2021 and held it in 2 quarters. The position peaked at $532K in Q2 2021. 87 funds tracked by Wall St. Rank hold IGMS as of Q4 2021.

  • Los Angeles Capital Management reported no remaining IGM Biosciences position as of Q4 2021 after selling out during the quarter.
  • Los Angeles Capital Management sold 6,400 IGM Biosciences shares in Q4 2021, an estimated $421K.
  • Los Angeles Capital Management first reported a position in IGM Biosciences in Q2 2021 and held it in 2 quarters.
  • Los Angeles Capital Management's IGM Biosciences position peaked at $532K in Q2 2021.
  • 87 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2021.

Based on Los Angeles Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.